期刊文献+

肝细胞癌系统治疗研究进展 被引量:4

Progress of systemic therapies in patients with hepatocellular carcinoma
下载PDF
导出
摘要 肝细胞癌(hepatocellular carcinoma,HCC)早期诊断率低,术后复发率高,缺乏有效治疗手段等导致患者预后不良。自索拉非尼和奥沙利铂取得成功后的近10年,多项临床研究折戟沉沙,一度使晚期HCC治疗捉襟见肘,举步维艰。近年来,随着瑞戈非尼、仑伐替尼、卡博替尼、雷莫芦单抗以及免疫检查点抑制剂取得的成功,使得HCC系统治疗逐渐丰富。本文回顾近10年来HCC的大型临床研究数据,分析HCC系统治疗的现状和未来研究方向。 The poor prognosis of hepatocellular carcinoma mainly results from low early diagnosis rate, high recurrence rate after surgery, and lacking of efficient treatment. After Sorafeinb and Oxliplantin achieved success in patients with hepatocellular carcinoma, majority of clinical trails failed to prolong patients survival. However, in recent years, the trails of Regorafeinb, Lenvatinib, Cabozantinib, Ramcirumab, and checkpoint inhibitors achieved positive outcomes, which enriched the strategies for advanced hepatocellular carcinoma. In this article, the current situation and future direction were analyzed after summarized the clinical trails above.
作者 郑侠 陈晓锋 ZHENG Xia;CHEN Xiao-feng(Department of Oncology,the 81 Hospital Affiliated Nanjing University of Chinese Medicine,Nanjing 210002,China;Department of Oncology,the First Affiliated Hospital of Nanjing Medical University,Nanjing 210029,China)
出处 《肿瘤综合治疗电子杂志》 2018年第3期37-43,共7页 Journal of Multidisciplinary Cancer Management(Electronic Version)
关键词 肝细胞癌 系统治疗 仑伐替尼 免疫检查点抑制剂 Hepatocellular carcinoma Systemic therapies Lenvatinib Immune checkpoint inhibtors
  • 相关文献

同被引文献58

引证文献4

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部